| Title |
Abundance of Flt3 and its ligand in astrocytic tumors
|
|---|---|
| Published in |
OncoTargets and therapy, May 2013
|
| DOI | 10.2147/ott.s43114 |
| Pubmed ID | |
| Authors |
Kirches, Wilisch-Neumann, Pachow, Eßbach, Nadine Andrae, Mawrin, Warnke |
| Abstract |
Molecular targeted therapies for astrocytic tumors are the subject of growing research interest, due to the limited response of these tumors, especially glioblastoma multiforme, to conventional chemotherapeutic regimens. Several of these approaches exploit the inhibition of receptor tyrosine kinases. To date, it has not been elucidated if fms-like tyrosine kinase-3 (Flt3) and its natural ligand (Flt3L) are expressed in astrocytic tumors, although some of the clinically intended small-molecule receptor tyrosine kinase inhibitors affect Flt3, while others do not. More importantly, the recent proof of principle for successful stimulation of the immune system against gliomas in preclinical models via local Flt3L application requires elucidation of this receptor tyrosine kinase pathway in these tumors in more detail. This therapy is based on recruitment of Flt3-positive dendritic cells, but may be corroborated by activity of this signaling pathway in glioma cells. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Doctoral Student | 3 | 19% |
| Student > Bachelor | 3 | 19% |
| Student > Ph. D. Student | 3 | 19% |
| Student > Master | 2 | 13% |
| Professor | 2 | 13% |
| Other | 3 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 38% |
| Biochemistry, Genetics and Molecular Biology | 5 | 31% |
| Agricultural and Biological Sciences | 2 | 13% |
| Unspecified | 1 | 6% |
| Social Sciences | 1 | 6% |
| Other | 1 | 6% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 June 2013.
All research outputs
#18,340,012
of 22,711,645 outputs
Outputs from OncoTargets and therapy
#1,484
of 2,927 outputs
Outputs of similar age
#144,821
of 192,821 outputs
Outputs of similar age from OncoTargets and therapy
#30
of 38 outputs
Altmetric has tracked 22,711,645 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,927 research outputs from this source. They receive a mean Attention Score of 2.6. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 192,821 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.